Jan 1, 2025 · Novel, potent and effective CDK4/6-HDAC dual-targeting agents were developed. N14 showed favorable synergistic efficacy in HCC cell lines and MCF-7 (ER + /HER2 -). N14 …

Our study suggests compound N14 is a novel dual-targeting CDK4/6-HDAC inhibitor that represents a promising treatment strategy for HCC. Keywords: Antitumor; Cyclin-dependent …

HDAC and CDK4/6 inhibitors are effective but are prone to drug resistance and failure as single agents. Therefore, we hypothesized that combining Abe and Pan could synergistically and …

Aug 29, 2023 · Adding CDK4/6, PI3K, mTOR and HDAC inhibitors to endocrine therapy has proven to be an effective second-line treatment strategy for patients with endocrine resistance.

We highlight the various mechanisms that are directly or indirectly responsible for resistance to CDK4/6 inhibitors, categorizing them into two broad groups; cell cycle‐specific mechanisms …

Aug 29, 2023 · mTOR inhibitor and CDK4/6 inhibitor-based regimens demonstrated superior clinical efficacy and comparable safety profiles as second-line treatment in patients with HR …

CDK4/6 inhibitors restore the cell cycle by selectively inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), and block cell proliferation in a variety of tumor cells, including those of breast cancer.

Herein, a series of novel CDK4/6 and HDAC dual-targeting inhibitors based on the moiety of palbociclib were designed and synthesized. Among them, compound N14 potently inhibited …

Aug 6, 2014 · Preclinical studies elucidating the mechanisms driving resistance to standard therapies have identified promising targets including cyclin-dependent kinase 4/6, …

Oct 5, 2018 · In particular, CDK4/6 functions as a critical activator of G1 phase progression. The aim of therapeutic CDK4/6 targeting in cancer cells is to stop cell proliferation and restore cell …